Antagonism of Cisplatin-induced Emesis by Metoclopramide and Dazopride Through Enhancement of Gastric Motility

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 1986 May 1

PMID 3698769

Citations 8

Authors

R S ALPHIN

A G Proakis

C A Leonard

W L Smith

W N DANNENBURG

W J Kinnier

D N Johnson

L F SANCILIO

J W Ward

Affiliations

Soon will be listed here.

Abstract

The antiemetic activity, gastric motor activity, and dopamine receptor effects of metoclopramide, dazopride, and sulpiride were assessed to establish if enhancement of gastric motility or antagonism of central dopamine receptors is the predominant action for drug-induced suppression of cisplatin-induced emesis. Emesis produced in dogs by cisplatin is antagonized by metoclopramide and dazopride. The antiemetic actions of metoclopramide and dazopride are associated with their ability to enhance gastric motor activity. Dazopride, unlike metoclopramide, has minimal dopamine receptor antagonist properties. Sulpiride is a potent dopamine receptor antagonist; however, it had no effect on the stomach and was ineffective in suppressing cisplatin-induced emesis.

Citing Articles

A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.

Sanger G, Andrews P Front Pharmacol. 2018; 9:913.

PMID: 30233361 PMC: 6131675. DOI: 10.3389/fphar.2018.00913.

Pharmacological Agents Affecting Emesis : A Review (Part II).

Mitchelson F Drugs. 2017; 43(4):443-463.

PMID: 28421555 DOI: 10.2165/00003495-199243040-00003.

Emesis in dogs: a review.

Elwood C, Devauchelle P, Elliott J, Freiche V, German A, Gualtieri M J Small Anim Pract. 2010; 51(1):4-22.

PMID: 20137004 PMC: 7167204. DOI: 10.1111/j.1748-5827.2009.00820.x.

Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy.

Grant S, Kris M, Gralla R, Clark R, Tyson L Cancer Chemother Pharmacol. 1993; 31(6):442-4.

PMID: 8453682 DOI: 10.1007/BF00685032.

Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis.

Miner W, Sanger G, Turner D Br J Cancer. 1987; 56(2):159-62.

PMID: 3311109 PMC: 2002136. DOI: 10.1038/bjc.1987.177.

References

Costall B, Naylor R . Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect?. Psychopharmacologia. 1973; 32(2):161-70. DOI: 10.1007/BF00428687. View

Creese I, Leff S . Dopamine receptors: a classification. J Clin Psychopharmacol. 1982; 2(5):329-35. View

Bass P, WILEY J . Contractile force transducer for recording muscle activity in unanesthetized animals. J Appl Physiol. 1972; 32(4):567-70. DOI: 10.1152/jappl.1972.32.4.567. View

Seigel L, Longo D . The control of chemotherapy-induced emesis. Ann Intern Med. 1981; 95(3):352-9. DOI: 10.7326/0003-4819-95-3-352. View

Kebabian J, Calne D . Multiple receptors for dopamine. Nature. 1979; 277(5692):93-6. DOI: 10.1038/277093a0. View

Droppleman D, Gregory R, ALPHIN R . A simplified method for assessing drug effects on gastric emptying in rats. J Pharmacol Methods. 1980; 4(3):227-30. DOI: 10.1016/0160-5402(80)90014-5. View

BORISON H, MCCARTHY L . Neuropharmacology of chemotherapy-induced emesis. Drugs. 1983; 25 Suppl 1:8-17. DOI: 10.2165/00003495-198300251-00003. View

Akwari O . The gastrointestinal tract in chemotherapy-induced emesis. A final common pathway. Drugs. 1983; 25 Suppl 1:18-34. DOI: 10.2165/00003495-198300251-00004. View

GYLYS J, DORAN K, Buyniski J . Antagonism of cisplatin induced emesis in the dog. Res Commun Chem Pathol Pharmacol. 1979; 23(1):61-8. View

10.

BORISON H, Wang S . Physiology and pharmacology of vomiting. Pharmacol Rev. 1953; 5(2):193-230. View

11.

Watling K, Dowling J . Dopaminergic mechanisms in the teleost retina. I. Dopamine-sensitive adenylate cyclase in homogenates of carp retina; effects of agonists, antagonists, and ergots. J Neurochem. 1981; 36(2):559-68. DOI: 10.1111/j.1471-4159.1981.tb01628.x. View

12.

Harrington R, HAMILTON C, Brogden R, Linkewich J, Romankiewicz J, Heel R . Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs. 1983; 25(5):451-94. DOI: 10.2165/00003495-198325050-00002. View

13.

Lu K, AMENOMORI Y, Chen C, Meites J . Effects of central acting drugs on serum and pituitary prolactin levels in rats. Endocrinology. 1970; 87(4):667-72. DOI: 10.1210/endo-87-4-667. View

14.

Leysen J, Gommeren W, Laduron P . Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol. 1978; 27(3):307-16. DOI: 10.1016/0006-2952(78)90233-2. View

15.

Gralla R . Metoclopramide. A review of antiemetic trials. Drugs. 1983; 25 Suppl 1:63-73. DOI: 10.2165/00003495-198300251-00007. View

16.

Laszlo J . Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983; 25 Suppl 1:1-7. DOI: 10.2165/00003495-198300251-00002. View

17.

Iwasaki Y, Kato Y, Chihara K, Ohgo S, Maeda K . Effect of sulpiride on plasma prolactin in rats. Neuroendocrinology. 1976; 21(3):267-74. DOI: 10.1159/000122532. View

18.

Brown B, Albano J, Ekins R, Sgherzi A . A simple and sensitive saturation assay method for the measurement of adenosine 3':5'-cyclic monophosphate. Biochem J. 1971; 121(3):561-2. PMC: 1176606. DOI: 10.1042/bj1210561. View

19.

LITCHFIELD Jr J, WILCOXON F . A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96(2):99-113. View

20.

TEDESCHI D, TEDESCHI R, Cook L, Mattis P, Fellows E . The neuropharmacology of trifluoperazine: a potent psychotherapeutic agent. Arch Int Pharmacodyn Ther. 1959; 122:129-43. View